Fibroheal develops silk protein–based biomaterials and advanced wound care products and has positioned itself as a pioneer in applying silk to clinical wound management. The company reports nine granted patents, more than 30 academic collaborations, and commercial adoption across over 500 hospitals in India with more than 150,000 patients treated to date. Fibroheal disclosed a 77% revenue growth in Q1 of FY2026–27 compared with the same quarter in the prior year. It has strategic partnerships including a February 2025 collaboration with US-based SYLKE and an ongoing study at Johns Hopkins on silk protein applications in donor sites. The firm’s pipeline includes Fibroplug ORC, a bioresorbable material for arresting internal bleeding post-surgery, and a bone regenerative solution for infected bone injuries and complex orthopaedic recoveries, both referenced for advancement toward a FY2027 launch. The company intends to use new funding to scale commercial operations, pursue regulatory readiness for developed markets, and expand its global footprint.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2026